BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12586138)

  • 1. Point of care measurement of lepirudin and heparin anticoagulation during systemic inflammation.
    Homoncik M; Pernerstorfer T; Reiter R; Knechtelsdorfer M; Quehenberger P; Jilma B
    Thromb Res; 2002 Oct; 108(1):91-5. PubMed ID: 12586138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia.
    Guy S; Kitchen S; Laidlaw S; Cooper P; Woolley A; Maclean R
    Br J Haematol; 2008 Jul; 142(3):466-8. PubMed ID: 18510685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lepirudin is a safe and effective anticoagulant for patients with heparin-associated antiplatelet antibodies.
    Mudaliar JH; Liem TK; Nichols WK; Spadone DP; Silver D
    J Vasc Surg; 2001 Jul; 34(1):17-20. PubMed ID: 11436069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lepirudin blunts endotoxin-induced coagulation activation.
    Pernerstorfer T; Hollenstein U; Hansen JB; Stohlawetz P; Eichler HG; Handler S; Speiser W; Jilma B
    Blood; 2000 Mar; 95(5):1729-34. PubMed ID: 10688831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.
    Greinacher A; Völpel H; Janssens U; Hach-Wunderle V; Kemkes-Matthes B; Eichler P; Mueller-Velten HG; Pötzsch B
    Circulation; 1999 Jan 5-12; 99(1):73-80. PubMed ID: 9884382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
    Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
    BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
    Seidel H; Kolde HJ
    Clin Appl Thromb Hemost; 2018 Mar; 24(2):287-294. PubMed ID: 28320219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of lepirudin in patients with heparin-induced thrombocytopenia and renal failure requiring hemodialysis.
    Dager WE; White RH
    Ann Pharmacother; 2001; 35(7-8):885-90. PubMed ID: 11485140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time.
    Perry SL; O'Shea SI; Ortel TL
    Blood Coagul Fibrinolysis; 2003 Sep; 14(6):601-4. PubMed ID: 12960616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous haemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin induced thrombocytopenia (HIT II).
    Schneider T; Heuer B; Deller A; Boesken WH
    Wien Klin Wochenschr; 2000 Jun; 112(12):552-5. PubMed ID: 10953874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia.
    Longrois D; de Maistre E; Bischoff N; Dopff C; Meistelman C; Angioï M; Lecompte T
    Can J Anaesth; 2000 Mar; 47(3):255-60. PubMed ID: 10730738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of subcutaneous lepirudin in an obese surgical intensive care unit patient with heparin resistance.
    Inman KR; Gerlach AT
    Ann Pharmacother; 2009 Oct; 43(10):1714-8. PubMed ID: 19690218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance.
    Eichler P; Friesen HJ; Lubenow N; Jaeger B; Greinacher A
    Blood; 2000 Oct; 96(7):2373-8. PubMed ID: 11001886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.
    Greinacher A; Janssens U; Berg G; Böck M; Kwasny H; Kemkes-Matthes B; Eichler P; Völpel H; Pötzsch B; Luz M
    Circulation; 1999 Aug; 100(6):587-93. PubMed ID: 10441094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies.
    Lubenow N; Eichler P; Lietz T; Farner B; Greinacher A
    Blood; 2004 Nov; 104(10):3072-7. PubMed ID: 15280202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of bedside prothrombin time and activated partial thromboplastin time measurement by coagulation analyzer CoaguCheck Plus in various clinical settings.
    Ruzicka K; Kapiotis S; Quehenberger P; Handler S; Hornykewycz S; Michitsch A; Huber K; Clemens D; Susan M; Pabinger I; Eichinger S; Jilma B; Speiser W
    Thromb Res; 1997 Sep; 87(5):431-40. PubMed ID: 9306617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis.
    Fischer KG; van de Loo A; Böhler J
    Kidney Int Suppl; 1999 Nov; (72):S46-50. PubMed ID: 10560805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lepirudin in heparin-induced thrombocytopenia and extracorporeal membranous oxygenation.
    Dager WE; Gosselin RC; Yoshikawa R; Owings JT
    Ann Pharmacother; 2004 Apr; 38(4):598-601. PubMed ID: 14982973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
    Dang CH; Durkalski VL; Nappi JM
    Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators.
    Becker RC; Ball SP; Eisenberg P; Borzak S; Held AC; Spencer F; Voyce SJ; Jesse R; Hendel R; Ma Y; Hurley T; Hebert J
    Am Heart J; 1999 Jan; 137(1):59-71. PubMed ID: 9878937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.